TAVALISSE (fostamatinib disodium)
SPLEEN/BRUTON'S TYROSINE KINASE INHIBITORS · SEVERE THROMBOCYTOPENIA IN REFRACTORY CHRONIC IMMUNE THROMBOCYTOPENIA PURPURA
RIGEL PHARMACEU
Drug class
Spleen/Bruton's Tyrosine Kinase Inhibitors
The exact phrase "Spleen/Bruton's Tyrosine Kinase Inhibitors" is an umbrella grouping rather than a single standardized regulatory drug class, referring jointly to targeted inhibitors of spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK). Read more about Spleen/Bruton's Tyrosine Kinase Inhibitors
4 drugs in this class 4 manufacturers
Drugs in Spleen/Bruton's Tyrosine Kinase Inhibitors
WAYRILZ (rilzabrutinib)
SPLEEN/BRUTON'S TYROSINE KINASE INHIBITORS · CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
GENZYME
RHAPSIDO (remibrutinib)
SPLEEN/BRUTON'S TYROSINE KINASE INHIBITORS · CHRONIC IDIOPATHIC URTICARIA ·+1
Novartis Pharmaceuticals
RHAPSIDO (remibrutinib)
SPLEEN/BRUTON'S TYROSINE KINASE INHIBITORS · CHRONIC IDIOPATHIC URTICARIA ·+1
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Spleen/Bruton's Tyrosine Kinase Inhibitors preselected. Add indication or manufacturer filters there.
The exact phrase "Spleen/Bruton's Tyrosine Kinase Inhibitors" is an umbrella grouping rather than a single standardized regulatory drug class, referring jointly to targeted inhibitors of spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK).
These agents block critical non-receptor protein kinases within B-cell receptor and Fc-receptor signaling cascades, thereby suppressing aberrant immune-cell proliferation, activation, and antibody-mediated destruction.
Clinically, BTK inhibitors are standard therapies for B-cell malignancies—such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia—while both SYK and BTK inhibitors are utilized or actively investigated for autoimmune and inflammatory disorders, most notably immune thrombocytopenia and chronic spontaneous urticaria.
-
nih.gov
The exact phrase "Spleen/Bruton's Tyrosine Kinase Inhibitors" is an umbrella grouping rather than a single standardized regulatory drug class, referring jointly to targeted inhibitors of spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK) These agents block critical non-receptor protein kinases within B-cell receptor and Fc-receptor signaling cascades, thereby suppressing aberrant immune-cell proliferation, activation, and antibody-mediated destruction
-
nih.gov
The exact phrase "Spleen/Bruton's Tyrosine Kinase Inhibitors" is an umbrella grouping rather than a single standardized regulatory drug class, referring jointly to targeted inhibitors of spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK)
-
nih.gov
These agents block critical non-receptor protein kinases within B-cell receptor and Fc-receptor signaling cascades, thereby suppressing aberrant immune-cell proliferation, activation, and antibody-mediated destruction Clinically, BTK inhibitors are standard therapies for B-cell malignancies—such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia—while both SYK and BTK inhibitors are utilized or actively investigated for autoimmune and inflammatory disorders,...
-
fda.gov
These agents block critical non-receptor protein kinases within B-cell receptor and Fc-receptor signaling cascades, thereby suppressing aberrant immune-cell proliferation, activation, and antibody-mediated destruction
-
nih.gov
Clinically, BTK inhibitors are standard therapies for B-cell malignancies—such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia—while both SYK and BTK inhibitors are utilized or actively investigated for autoimmune and inflammatory disorders, most notably immune thrombocytopenia and chronic spontaneous urticaria
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.